<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02905539</url>
  </required_header>
  <id_info>
    <org_study_id>P-0101</org_study_id>
    <secondary_id>2015-004808-36</secondary_id>
    <secondary_id>U1111-1176-4563</secondary_id>
    <secondary_id>DRKS00010766</secondary_id>
    <nct_id>NCT02905539</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer</brief_title>
  <acronym>HOMe_aFers_1</acronym>
  <official_title>A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität des Saarlandes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität des Saarlandes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine to what extend a treatment with the iron compounds&#xD;
      Iron Isomaltoside 1000 or Ferric Carboxymaltose is leading to hypophosphatemia and to study&#xD;
      the potential clinical impact of hypophosphatemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies suggested that intravenous iron preparations for anemia treatment may have&#xD;
      adverse effects on phosphorus regulation, as they may induce an increase in the phosphaturic&#xD;
      hormone Fibroblast Growth Factor-23 (FGF-23) and a subsequent fall in plasma phosphorus&#xD;
      levels.&#xD;
&#xD;
      So far it is unknown if these effects are class- or substance-specific.&#xD;
&#xD;
      This study will address the question whether among female participants with iron deficiency&#xD;
      anemia the application of ferric-(III)-derisomaltose and ferric carboxymaltose will cause&#xD;
      episodes of hypophosphatemia to same extend. The investigators will additionally compare the&#xD;
      effects of the two iron preparations on other parameters of calcium-phosphate metabolism, and&#xD;
      decipher potential consequences of hypophosphatemia by analysing cardiac function,&#xD;
      immunological parameters and quality of life.&#xD;
&#xD;
      In order to investigate these outcomes, 60 women with iron deficient anemia will be&#xD;
      randomised to receive either ferric-(III)-derisomaltose or ferric carboxymaltose.&#xD;
&#xD;
      The monocentric study will be conducted at Saarland University Medical Center. For each&#xD;
      participating woman, the study comprises five visits to the study center during a period of&#xD;
      five weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of hypophosphatemia</measure>
    <time_frame>From baseline to day 35</time_frame>
    <description>The incidence of hypophosphatemia is defined as a drop of serum phosphate below 2.0 mg/dl.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of plasma phosphate concentrations.</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of fractional Phosphate urinary excretion.</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Plasma Vitamin D (active, inactive).</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of fibroblast growth factor 23 (intact and c-terminal).</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of parathyroid Hormone.</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Plasma calcium.</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Plasma alkaline Phosphatase.</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Plasma soluble Klotho.</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Plasma Hepcidin-25.</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Serum N-Terminal Propeptide of Type I Collagen (PINP).</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Pyridinoline (PYD) in the urine</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Quality of life.</measure>
    <time_frame>From baseline to day 35</time_frame>
    <description>German Version of the Short Form (36) Health Survey by Matthias Morfeld, Inge Kirchberger, Monika Bullinger.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of (supra)ventricular cardiac arrhythmias in the ambulatory Electrocardiography.</measure>
    <time_frame>Before and 7 days after administration of iron compound</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of QT-time in the 12-lead Electrocardiography.</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of QT-Dispersion in the 12-lead Electrocardiography.</measure>
    <time_frame>From baseline to day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Left Ventricular Mass Index</measure>
    <time_frame>From baseline to day 7</time_frame>
    <description>Echocardiographic measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of monocyte subpopulations.</measure>
    <time_frame>Right before the singular infusion of the iron compound is started and right after infusion of the iron compound is completed.</time_frame>
    <description>Count of classical , intermediate and nonclassical monocytes using flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of phagocytic capacity of monocytes.</measure>
    <time_frame>Right before the singular infusion of the iron compound is started and right after the infusion of iron compound is completed.</time_frame>
    <description>Exposition of Monocytes to Fluoresbrite Yellow Green (YG) Carboxylate Microspheres and subsequent flow cytometric count of Fluorescein isothiocyanate-positive Monocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of fatigue</measure>
    <time_frame>From baseline to day 35</time_frame>
    <description>The German Version of the Multidimensional Fatigue Inventory. (Smets E. M. A., Garssen B., Bonke B. and Haes de J. C. J. M. (1995). The Multidimensional Fatigue Inventory (MFI); Psychometric qualities of an instrument to assess fatigue. Journal of Psychosomatic Research, 39, 315-325.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Left Atrial Volume Index</measure>
    <time_frame>From Baseline to day 7</time_frame>
    <description>Echocardiographic measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Systolic Ejection Fraction</measure>
    <time_frame>From Baseline to day 7</time_frame>
    <description>Echocardiographic measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Diastolic Left Ventricular Function</measure>
    <time_frame>From Baseline to day 7</time_frame>
    <description>Echocardiographic measurement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Anemia, Iron-Deficiency</condition>
  <arm_group>
    <arm_group_label>Iron Isomaltoside 1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive Iron Isomaltoside 1000 solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferric Carboxymaltose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receive Ferric Carboxymaltose solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Isomaltoside 1000</intervention_name>
    <arm_group_label>Iron Isomaltoside 1000</arm_group_label>
    <other_name>Monofer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Carboxymaltose</intervention_name>
    <arm_group_label>Ferric Carboxymaltose</arm_group_label>
    <other_name>Ferinject</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written informed consent,&#xD;
&#xD;
          -  female,&#xD;
&#xD;
          -  gynecological blood losses,&#xD;
&#xD;
          -  age ≥ 18 years,&#xD;
&#xD;
          -  iron deficiency anemia,&#xD;
&#xD;
          -  Hemoglobin &lt; 12,0 g/dl,&#xD;
&#xD;
          -  Serum-Ferritin ≤ 100 ng/ml or Serum-Ferritin ≤ 300 ng/ml and Transferrin-saturation ≤&#xD;
             30 %,&#xD;
&#xD;
          -  Intolerance to or inefficacy of an oral iron supplement&#xD;
&#xD;
          -  estimated Glomerular Filtration Rate &gt; 15 ml/min/1.73 m²&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known hypersensitivity to MonoFer® or FERINJECT®,&#xD;
&#xD;
          -  severe, known hypersensitivity to other intravenous iron preparations,&#xD;
&#xD;
          -  Plasma Phosphate &lt; 2.5 mg/dl at screening,&#xD;
&#xD;
          -  Hemochromatosis,&#xD;
&#xD;
          -  Untreated hyperparathyroidism,&#xD;
&#xD;
          -  Renal replacement therapy/kidney transplantation,&#xD;
&#xD;
          -  Active malignant disease, disease-free survival for less than 5 years,&#xD;
&#xD;
          -  Intravenous iron administration within the last 30 days,&#xD;
&#xD;
          -  Treatment with erythropoietin or erythropoietin-stimulating agents, transfusion of red&#xD;
             blood cells, radiotherapy or chemotherapy within the last 60 days,&#xD;
&#xD;
          -  Surgery under anesthetic within the last 10 days,&#xD;
&#xD;
          -  Alanine transaminase (ALT) or aspartate transaminase (AST) &gt; 1.5 fold above levels in&#xD;
             healthy individuals,&#xD;
&#xD;
          -  Acute febrile infections within the last 7 days,&#xD;
&#xD;
          -  Chronic inflammatory diseases requiring a systemic antiinflammatory treatment,&#xD;
&#xD;
          -  self-reported severe asthma or eczema,&#xD;
&#xD;
          -  presence of relative contraindications (any allergy, any immunologic or inflammatory&#xD;
             disease, history of atopic allergies), for which a treatment with the medicinal&#xD;
             investigational products is not deemed indicated by the investigator,&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  women of childbearing potential without an effective method of contraception,&#xD;
&#xD;
          -  lactating women,&#xD;
&#xD;
          -  Present alcohol or drug dependency,&#xD;
&#xD;
          -  Patients with a history of a psychological illness or seizures,&#xD;
&#xD;
          -  Non-compliance or administration of any investigational drug within 30 days preceding&#xD;
             the study start.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Heine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universität des Saarlandes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danilo Fliser, MD</last_name>
    <role>Study Director</role>
    <affiliation>Universität des Saarlandes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron</keyword>
  <keyword>anemia</keyword>
  <keyword>phosphorus</keyword>
  <keyword>FGF-23</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron isomaltoside 1000</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

